Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunglobulin replacement
Main Article Content
Keywords
IVIG, Primary immunodeficiency, Adverse reactions
Abstract
Objectives: We aimed to determine adverse reactions and influencing factors, within the scope of the number of patients and total infusions, in patients with primary immunodeficiencies receiving intravenous immunoglobulin (IVIG) replacement.
Materials and methods: Children with primary immunodeficiencies receiving IVIG replacement in Izmir Dr Behcet Uz Children’s Hospital, between June 2014 and June 2016, were included in our study.
Results: The total number of the patients receiving IVIG replacement was 145 (37 female, 108 male). The number of total IVIG infusions was 1214. Adverse reactions were observed in 44.8% of the patients and 14.2% of the infusions. Common variable immunodeficiency was the most common diagnosis of the patients and adverse reactions most commonly developed in this group (24.2%). In all infusions the most frequent adverse reaction was headache (7.8%); fever was the most frequent immediate side effect (3.9%), whereas headache was the most common delayed adverse effect (5.1%). By logistic regression analyses, history of adverse reaction to IVIG in previous infusions, existence of concomitant infectious disease, past or family history of atopic disease, to receive IVIG infusion at the first time, or being under 10 years old were found associated with adverse reactions. There was no correlation between the concentration of IVIG preparations and the rate of side-effect development.
Conclusions: In our study no severe adverse reaction to IVIG was observed, but many mild or moderate side effects occurred. Therefore, IVIG indications must be well-identified. Patients, family of the patients and health care workers must be informed for adverse reactions.
References
2. Wilson NW, Bastian JF. New uses of intravenous immunoglobulin therapy. West J Med. 1991;154:461.
3. Friedli HR. Methodology and safety considerations in the produciton of an intravenous immunoglobulin preparation. Pharmacotherapy. 1987;7:36-40.
4. Simon HU, Spath PJ. IVIG-mechanism of action. Allergy. 2003;58:543-52.
5. Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet. 1987;9:1075-7.
6. Pirofsky B. Intravenous immunoglobulin therapy in hypogammaglobulinemia. A review. Am J Med. 1984;30:53-60.
7. Azizi G, Abolhassani H, Asgardoon MH, Rahnavard J, Dizaji MZ, Yazdani R, Mohammadi J, Aghamohammadi A. The use of immunoglobulin therapy in primary immunodeficiency diseases. Endocr Metab Immune Disord Drug Targets. 2016;16:80-8.
8. Azizi G, Abolhassani H, Asgardoon MH, Shaghaghi S, Negahdari B, Mohammadi J, Rezaei N, Aghamohammadi A. Managing patients with side effects and adverse events to immunoglobulin therapy. Expert Rev Clin Pharmacol. 2016;9(1):91-102.
9. Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27:171-8.
10. Richard Stiehm E. Adverse effects of human immunoglobulin therapy. Transf Med Rev. 2013;27:171-8.
11. Donofrio PD, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, et al. Safety and tolerability of immunoglobulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol. 2010;67:1082-8.
12. Struff WG, Klasser M, Eckert V, Dietrich RL. Safety monitoring of a polyvalent immunoglobulin preparation: documentation of 15,548 administrations. Int J Clin Pharmacol Toxicol. 2005;43:420-8.
13. Shroeder HW Jr, Dougherty CJ. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infection. 2012;40:601-11.
14. Brennan VM, Salome-Bentley NJ, Chapel HM. Prospective audit of adverse reactions occurring in 459 primary antibody deficient patients receiving intravenous immunoglobulin. Lancet. 2003;133:247-51.
15. Singh-Grewal D, Kemp A, Wong M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions. Arch Dis Childhood. 2006;91:651-4.
16. Bichuetti-Silva DC, Furlan FP, Nobre FA, Pereira CT, Gonc¸alves TR, Gouveia-Pereira M, et al. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions. Int Immunopharmacol. 2014;23:442-6.
17. Gislason D, Hanson LA, Kjellman H, Ljunggren C, Malmberg R. Intravenous gamma-globulin infusions in patients with hypogamma-globulinemia: prevention of adverse reactions with corticosteroids. Vox Sang. 1978;34:143-8.
18. Centers for Disease Control and Prevention. Renal insufficiency and failure associated with immunoglobulin intravenous therapy-United States, 1995-1998. MMWR. 1999;48:518-21.
19. Schiff RI. ˙Intravenous immunoglobulin, pharmacology, clinical uses and mechanism of action. Pediatr Allergy Immunol. 1994;5:127-56.
20. Tam DA, Morton LD, Stroncek DF. Neutropenia in a patient receiving intravenous immunoglobulin. J Neurol Immunol. 1996;64:175-8.
21. Brox AG, Cournoyer D, Sternbach M. Hemolytic anemia following intravenous gammaglobulin administration. Am J Med. 1987;82:633-5.
22. Kessary-Shoham H, Levy Y, Shoenfeld Y. In vivo administration of intravenous immunoglobulin can lead to enhanced erythrocytese questration. J Autoimmun. 1999;13:129-35.
23. Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve. 1997;20:1102-7.
24. Go RS, Call TG. Deep venosus thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin related thrombotic complications. Mayo Clinic Proc. 2000;75:83-5.
25. Dashti-Khavidaki S, Aghamohammadi A, Farshadi F, Movahedi M, Parvaneh N, Pauladi N, et al. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. J Investig Allergol Clin Immunol. 2009;19:139-45.
26. Kaba S, Keskindemirci G, Aydogmus C, Siraneci R, Erol Cipe F. Immediate adverse reactions to intravenous immunoglobulin in children: a single-center experience. Eur Ann Allergy Clin Immunol. 2017;49:11-4.
27. Palabrica FR, Kwong SL, Padua FR. Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study. Asia Pac Allergy. 2013;3:249-56.
28. Zimring JC. Do immune complexes play a role in hemolytic sequelae of intravenous immune globulin? Transfusion. 2015;55 Suppl 2:86-9.
29. Ameratunga R, Sinclair J, Kolbe J. Increased risk of adverse events when changing intravenous immunoglobulin preparations. Clin Exp Immunol. 2004;136:111-3.
30. Wasserman RL, Church JA, Stein M, Moy J, White M, Forbes L, et al. Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency. J Clin Immunol. 2012;32:663-9.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.